Difficulty: Medium
Average Score: 75%
Practice
All of the following drugs are immune checkpoint inhibitors for treatment of metastatic renal cell carcinoma, Except:
Correct answer
A
Rationale
Bevacizumab is a VEGF inhibitor blocks angiogenesis, not an immune checkpoint inhibitor (e.g., PD-1/CTLA-4). Pembrolizumab, Ipilimumab, and Nivolumab target immunity enhance T-cell response in metastatic RCC. Bevacizumab's vascular mechanism distinguishes it, critical for differentiating therapies, unlike immune-boosting drugs.